Keenan, Tanya E.
Guerriero, Jennifer L. http://orcid.org/0000-0002-2104-5457
Barroso-Sousa, Romualdo
Li, Tianyu
O’Meara, Tess http://orcid.org/0000-0002-4778-2842
Giobbie-Hurder, Anita http://orcid.org/0000-0003-2496-7737
Tayob, Nabihah
Hu, Jiani
Severgnini, Mariano
Agudo, Judith
Vaz-Luis, Ines
Anderson, Leilani
Attaya, Victoria
Park, Jihye
Conway, Jake
He, Meng Xiao
Reardon, Brendan
Shannon, Erin
Wulf, Gerburg http://orcid.org/0000-0001-7868-6231
Spring, Laura M.
Jeselsohn, Rinath
Krop, Ian
Lin, Nancy U.
Partridge, Ann
Winer, Eric P.
Mittendorf, Elizabeth A.
Liu, David
Van Allen, Eliezer M. http://orcid.org/0000-0002-0201-4444
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Article History
Received: 12 February 2021
Accepted: 31 August 2021
First Online: 21 September 2021
Competing interests
: R.B.-S. has served as an advisor/consultant to Eli Lilly and has received honoraria from Roche for participation in Speakers Bureau. J.L.G. is a consultant for GlaxoSmithKline (GSK), Array BioPharma, Codagenix, Verseau, and Kymera and receives sponsored research support from GSK, Eli Lilly, and Array BioPharma. I.V.L. has received institutional honoraria from Pfizer, AstraZeneca, and Amgen. M.X.H. has been a consultant to Amplify Medicines and Ikena Oncology. L.M.S. has been a consultant/advisor for Novartis and Avrobio. N.U.L. has received institutional research funding from Genentech, Cascadian Therapeutics, Array Biopharma, Seattle Genetics, Novartis, Merck, and Pfizer and has been a consultant/advisor to Seattle Genetics, Puma, and Daichii Sankyo. E.P.W. receives consulting fees from InfiniteMD and Leap Therapeutics, honoraria from Genentech, Roche, Tesaro, Lilly, and institutional research funding from Genentech. E.A.M. reports personal financial interests: research support for lab from GlaxoSmithKline; honoraria from Physician Education Resource; compensated service on Scientific Advisory Boards for AstraZeneca, Exact Sciences (formerly Genomic Health), Merck, Peregrine Pharmaceuticals, Roche/Genentech, Sellas Lifesciences, TapImmune Inc; uncompensated service on Steering Committees for BMS, Lilly, Roche/Genentech. E.A.M. reports institutional financial interests from MD Anderson: clinical trial funding from AstraZeneca, EMD Serono, Galena Biopharma, Roche/Genentech; and institutional financial interests from DFCI: clinical trial funding from Roche/Genentech (via SU2C grant). E.M.V.A. serves as a consultant/advisor to Tango Therapeutics, Invitae, Genome Medical, Dynamo, Foresite Capital, and Illumina; holds research support from Novartis and Bristol-Myers Squibb; and holds equity in Synapse, Genome Medical, Tango, and Microsoft Corp. S.M.T. receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an advisor/consultant to AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Puma, Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, and Samsung Bioepsis Inc. The remaining authors declare no competing interests.